{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/addisons-disease/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"ddd590cd-acdd-5ec5-8adc-56c10d49145e","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 25bf9212-5650-4b24-b04a-d905dc8254c4 --><h2>Changes</h2><!-- end field 25bf9212-5650-4b24-b04a-d905dc8254c4 -->","summary":null,"htmlStringContent":"<!-- begin item 24085dbe-9ae8-4cbc-bcbd-31372840031b --><!-- begin field 89a0a99c-abee-4a89-a9b2-6f35b7691df0 --><p><strong>December 2020</strong> — reviewed. A literature search was conducted in November 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic.</p><!-- end field 89a0a99c-abee-4a89-a9b2-6f35b7691df0 --><!-- end item 24085dbe-9ae8-4cbc-bcbd-31372840031b -->","topic":{"id":"85552d74-8915-56ec-961e-2cbd611bb10a","topicId":"b9b069a1-e345-435c-8996-0f9b9532b3b3","topicName":"Addison's disease","slug":"addisons-disease","lastRevised":"Last revised in December 2020","chapters":[{"id":"5bb9a13a-2651-51da-9586-419b958fc24f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d1ae168c-5219-526e-967a-65c44cfe1635","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1e817e04-330a-5085-a1a4-705eedbc89f4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"ddd590cd-acdd-5ec5-8adc-56c10d49145e","slug":"changes","fullItemName":"Changes"},{"id":"904ce186-aff5-51bf-a48a-7302aa46f685","slug":"update","fullItemName":"Update"}]},{"id":"6dbcee75-0365-5555-a1cd-832f4af24189","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e1642c54-2720-5915-a5be-5fd600b124ca","slug":"goals","fullItemName":"Goals"},{"id":"7825ef20-439f-5a33-a1ae-2d755d692128","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2e7aa18d-cc25-541c-ab7f-4b19f3d06de0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"db1986d0-14c7-5a6c-969a-00655c4a668f","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"81632eb8-f3bc-567b-8133-c41a4d4a4fa2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"81b3a0d1-c071-5892-a290-537f0200588d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5d7951b5-eadd-5c95-8e28-85b6b87c2f84","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"79a65204-8744-50b7-8bd3-20e68fa2deda","slug":"definition","fullItemName":"Definition"},{"id":"8ebee041-b08d-5992-8fa2-bb3c352139ce","slug":"causes","fullItemName":"Causes"},{"id":"61809560-acc8-50ce-a0d9-9cb61f4f9626","slug":"prevalence","fullItemName":"Prevalence"},{"id":"17d23b10-c34e-5042-866b-bee0409de21e","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"09e08490-22fd-533a-b608-ce8f9f582c4b","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3c6f99c1-f2df-5737-90e6-e76b6d46aca8","slug":"complications","fullItemName":"Complications"}]},{"id":"c7ea2e16-11fc-593d-93d1-3e5925230b95","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8a3c3cb0-df69-59af-ad90-59ea47f3334b","slug":"suspecting-addisons-disease","fullItemName":"Suspecting Addison's disease"},{"id":"06bbc518-94d9-5d80-9034-38d9fc908d11","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"1f586755-4c6f-517b-bf1a-11bc2c316b17","slug":"investigations-suspected-adrenal-insufficiency","fullItemName":"Investigations - suspected adrenal insufficiency"},{"id":"1f8be7d7-2b02-57ef-b9eb-e0311516195c","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"}]},{"id":"4f82a73e-a473-59f7-a364-72430effad0e","fullItemName":"Management","slug":"management","subChapters":[{"id":"821e3bea-ed78-52fe-84d5-48a1178fb408","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"388a3da2-1859-52c3-a2cc-af8f499f9f2f","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"356babd6-ce13-538d-a8e9-d08f6fda5e57","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a075c8c7-e63f-5c68-b273-5dcda49584e7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"278a095e-2c76-50e4-ad8d-f3516b51a1e8","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d79162d2-ea8d-55fd-836e-ea1ad829d735","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"47224ede-71c8-5986-90e0-aa7e07da9461","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3e6e08a5-28f2-51f5-a9e0-4408814a4bed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"d5b26a91-7f89-52f2-a6b2-b9373ef97515","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1e817e04-330a-5085-a1a4-705eedbc89f4","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"822ecc72-4dde-54f2-9ef4-35e001b5277c","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 00c236ac-6b36-41f5-a2e3-958dd6ed3157 --><h3>Previous changes</h3><!-- end field 00c236ac-6b36-41f5-a2e3-958dd6ed3157 -->","summary":null,"htmlStringContent":"<!-- begin item 4ed92416-6635-4c8d-86cb-37b637cfca83 --><!-- begin field 444cf197-41bb-4ee5-81ef-75dd0b20f957 --><p><strong>September 2020</strong> — minor update. Information that people with Addison's disease taking an equivalent dose of 20 mg prednisolone or more per day should receive the pneumococcal vaccination has been added to this topic.</p><p><strong>February to March 2016</strong> — reviewed. A literature search was conducted in January 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. There have been minor changes to the recommendations on corticosteroid dosing during intercurrent illness, and it is now recommended that an adrenocorticotrophic hormone stimulation (Synacthen<sup>®</sup>) test should be carried out in secondary care.</p><p><strong>May 2014</strong> — minor update. Change to the section on choice of hydrocortisone preparation for the treatment of adrenal crisis.</p><p><strong>October 2010</strong> — minor update. Text regarding DHEA replacement therapy (unlicensed) reworded to reflect that this may be prescribed by some specialists. Issued in October 2010.</p><p><strong>May to September 2010</strong> — this is a new CKS topic. The evidence-base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field 444cf197-41bb-4ee5-81ef-75dd0b20f957 --><!-- end item 4ed92416-6635-4c8d-86cb-37b637cfca83 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}